MD Anderson acquires inducible switch technologies for cell therapy
Â鶹ӳ»Â MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe® switch platform and the GoCAR® platform. The transaction also includes clinical-grade stocks of rimiducid, an agent used to trigger the switches.
As a result of this acquisition, MD Anderson may incorporate these platforms into its own cell therapy...
MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy
Â鶹ӳ» MD Anderson Cancer Center and C-Biomex Ltd. today announced a strategic research collaboration agreement to co-develop...